Adalimumab treatment of life-threatening tuberculosis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 19364287.
- Also identified by DOI 10.1086/598504.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Most guidelines call for the discontinuation of treatment with tumor necrosis factor blockers in patients who develop tuberculosis. We report a case of life-threatening tuberculosis paradoxical reaction involving the lungs caused by withdrawal of the anti-tumor necrosis factor antibody adalimumab. Clinical improvement occurred only after resumption of adalimumab treatment.
Medical subject headings
- Anti-Inflammatory Agents
- Antibodies, Monoclonal
- Tuberculosis, Pulmonary